Non-Invasive Device Gets FDA Clearance for Migraine Treatment, Prevention in Younger Patients

The FDA has granted marketing clearance for eNeura’s single-pulse transcranial magnetic stimulation (sTMS) device for use in patients ≥12 years for the acute and prophylactic treatment of migraine.